Epix develops contrast agent for whole body angiography
This article was originally published in Clinica
Executive Summary
Epix Medical wants the cardiovascular surgeon to begin thinking of arterial plaque as a systemic disease. The company, which is in Phase III clinical trials with its MRI contrast imaging agent, AngioMark, predicts that when the agent is approved, prospects open up for physicians to use it together with MRI to supplant cholesterol testing as a diagnostic screening technique.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.